Special Issue "Nanoparticles in Neurology"

A special issue of Nanomaterials (ISSN 2079-4991).

Deadline for manuscript submissions: closed (30 November 2017).

Special Issue Editor

Dr. Angelina Angelova
Website
Guest Editor
CNRS UMR 8612 "Institut Galien Paris-Sud", Paris-Sud 11 University, Paris-Saclay University, F-92296 Châtenay Malabry, France
Interests: lipid/protein nanoassemblies; liquid crystalline phases; cubosomes; self-assembled nanostructures and nanoparticles with neuroprotective properties; protein and peptide-based nanomedicines; nanocarriers for macromolecular drug delivery; membrane receptor nanoscale organization; lipids; peptides; BDNF; cyclodextrin; soft nanomaterials
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Development of therapeutic systems for targeting the central nervous system (CNS) in neurological disorders is quite challenging and requires new concepts to achieve neuronal and synaptic repair, as well as neurogenesis in adult brain. Recent evidence suggests that macromolecular drugs (antibodies and other therapeutic proteins, peptides, and nucleic acids) provide higher efficiency and specificity as compared to small molecular weight compounds. However, these molecules have very low bioavailability and marginal capacity to cross the blood-brain barrier (BBB).

This Special Issue focuses on emergent neuronanomedicines derived from functionalized nanoparticles that may cross the BBB and deliver therapeutic molecules to target sites in the CNS. Topical delivery by nanocarriers exerting disease-modifying action on neurodegenerative and other neurological disorders will be of special interest. All kinds of nanocarrier formulations that may show neuroprotective activity, recovery from oxidative stress and ischemic injury as well as slow down and prevent neurodegeneration, will be considered in view of potential translational research in pathologies such as Alzheimer’s disease, Parkinson’s disease, Hungtington’s disease, stroke, amyotrophic lateral sclerosis, Rett syndrome, hearing impairment, spinal cord injury, multiple sclerosis, etc.

Dr. Angelina Angelova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted delivery to the CNS

  • nanocarriers of peptide and proteins drugs

  • nanocarriers of nucleic acids

  • nanoparticles with disease-modifying action on neurodegenerative disorders

  • nanoparticles for synaptic repair

  • neuropharmacology of nanomaterials

  • neurogenesis, neuroprotection, neuroplasticity, neurotoxicity

  • nanoparticles for recovery from oxidative stress and ischemic injury

  • nanoparticles and intracellular signaling pathways

  • neuronanomedicines derived from lipid, polymer, mesoporous or hybrid nanomaterials

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Microglial Immune Response to Low Concentrations of Combustion-Generated Nanoparticles: An In Vitro Model of Brain Health
Nanomaterials 2018, 8(3), 155; https://doi.org/10.3390/nano8030155 - 09 Mar 2018
Cited by 3
Abstract
The brain is the central regulator for integration and control of responses to environmental cues. Previous studies suggest that air pollution may directly impact brain health by triggering the onset of chronic neuroinflammation. We hypothesize that nanoparticle components of combustion-generated air pollution may [...] Read more.
The brain is the central regulator for integration and control of responses to environmental cues. Previous studies suggest that air pollution may directly impact brain health by triggering the onset of chronic neuroinflammation. We hypothesize that nanoparticle components of combustion-generated air pollution may underlie these effects. To test this association, a microglial in vitro biological sensor model was used for testing neuroinflammatory response caused by low-dose nanoparticle exposure. The model was first validated using 20 nm silver nanoparticles (AgNP). Next, neuroinflammatory response was tested after exposure to size-selected 20 nm combustion-generated nanoparticles (CGNP) collected from a modern diesel engine. We show that low concentrations of CGNPs promote low-grade inflammatory response indicated by increased pro-inflammatory cytokine release (tumor necrosis factor-α), similar to that observed after AgNP exposure. We also demonstrate increased production of reactive oxygen species and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p65 phosphorylation in microglia after CGNP stimulation. Finally, we show conditioned media from CGNP-stimulated microglia significantly reduced hypothalamic neuronal survival in vitro. To our knowledge, this data show for the first time that exposure to AgNP and CGNP elicits microglial neuroinflammatory response through the activation of NF-κB. Full article
(This article belongs to the Special Issue Nanoparticles in Neurology)
Show Figures

Graphical abstract

Open AccessArticle
Hyaluronan-Based Nanohydrogels as Effective Carriers for Transdermal Delivery of Lipophilic Agents: Towards Transdermal Drug Administration in Neurological Disorders
Nanomaterials 2017, 7(12), 427; https://doi.org/10.3390/nano7120427 - 04 Dec 2017
Cited by 8
Abstract
We suggest a convenient nanoemulsion fabrication method to create hyaluronan (HA)-based nanohydrogels for effective transdermal delivery. First, hyaluronan-conjugated dodecylamine (HA–Do) HA-based polymers to load the lipophilic agents were synthesized with hyaluronan (HA) and dodecylamine (Do) by varying the substitution ratio of Do to [...] Read more.
We suggest a convenient nanoemulsion fabrication method to create hyaluronan (HA)-based nanohydrogels for effective transdermal delivery. First, hyaluronan-conjugated dodecylamine (HA–Do) HA-based polymers to load the lipophilic agents were synthesized with hyaluronan (HA) and dodecylamine (Do) by varying the substitution ratio of Do to HA. The synthetic yield of HA–Do was more than 80% (HA–Do (A): 82.7 ± 4.7%, HA–Do (B): 87.1 ± 3.9% and HA–Do (C): 81.4 ± 4.5%). Subsequently, nanohydrogels were fabricated using the nanoemulsion method. Indocyanine green (ICG) simultaneously self-assembled with HA–Do, and the size depended on the substitution ratio of Do in HA–Do (nanohydrogel (A): 118.0 ± 2.2 nm, nanohydrogel (B): 121.9 ± 11.4 nm, and nanohydrogel (C): 142.2 ± 3.8 nm). The nanohydrogels were delivered into cells, and had excellent biocompatibility. Especially, nanohydrogel (A) could deliver and permeate ICG into the deep skin layer, the dermis. This suggests that nanohydrogels can be potent transdermal delivery systems. Full article
(This article belongs to the Special Issue Nanoparticles in Neurology)
Show Figures

Graphical abstract

Back to TopTop